Product Images Pemetrexed

This is a description for a medical product called Pemetrexed Injection. It is a hazardous drug that should be stored in its original carton within a temperature range of 20°C–25°C or can be stored in the fridge for 24 hours after dilution. It is a sterile injection and should be discarded if unused. The recommended dosage is not given, and users are directed to consult the prescribing information. The drug composition contains 25 mg pemetrexed equivalent to 27.57 mg pemetrexed disodium, 15 mg of citric acid, 4.4 mg of monothioghycerol, and 0.5 mg of L-methiorine. Sodium Chloride Injection may be added to adjust pH.*

This is a pharmaceutical product description for Pemetrexed, which is used for intravenous infusion. The text provides information about the recommended dosage, storage conditions, and dilution procedure. The product comes in a 34mL single-dose vial and contains 26mg of pemetrexed per mL. The text also includes warnings about the hazardous nature of the drug and instructions for discarding unused portions. Instructions are given for diluting the solution before administration, and it is recommended that the solution be refrigerated before and after dilution. The text also mentions the manufacturer and includes their contact information.*

This is a description of a drug called Pemetrexed Injection, which is meant for intravenous infusion. The drug comes in a single dose vial and has a recommended dosage that should be adhered to. The drug product solution must be diluted before administration and the diluted solution should be stored in refrigerated conditions for up to 24 hours. The drug is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India, and is distributed by Accord Healthcare, Inc.*

This text is a description of a drug, Pemetrexed, in the form of a 100 mg/4 mL injection administered by IV infusion. The drug is a hazardous substance and must be stored in suitable conditions. It is supplied in 4mL single-dose vials and discarded after usage. The prescribed dosage should be followed, and the drug should be diluted before administration. The drug's chemical composition and ingredients are listed, including, amongst others, pemetrexed, ciric acid, monothioglycerol, and sodium chloride injection. The text also provides information about the storage of the diluted solution and the details of the manufacturer of the drug.*

The text appears to be a table that shows two different treatment options for a medical condition. One option is to use a combination of medications called Pemetrexed and Cisplatin (PC) and the other option is to use Gemcitabine and Cisplatin (GC). The table shows the survival time of patients in months, with the number of patients at risk for both treatments. However, a significant part of the text is not useful and appears to be errors.*

This appears to be a table showing survival time in months for two different treatments for a medical condition. The treatments are listed as "Pemetrexed + Cisplatin (PC)" and "Gemcitabine + Cisplatin (GC)". The table also shows the number of patients at risk over time for each treatment.*

This text describes a survival probability chart that compares the effectiveness of two chemotherapy treatments, Pemetrexed + Cisplatin and Gemcitabine + Cisplatin. The chart shows the number of patients at risk for each treatment at 3, 6, and 9 months, as well as the survival time (in months) for each group up to 30 months.*

This appears to be a table or graph indicating the survival probability and time for patients receiving two different treatments, Pemetrexed and Pacbo. The x-axis is labeled as Survival Time in months and the y-axis appears to show the number of Patients at Risk for each treatment group. However, the rest of the text is not recognizable or readable, likely due to poor quality or formatting.*

This data appears to be a table showing survival probability and survival time for two groups of patients (Pemetexed and Pacsbo). It includes the number of patients at risk for each month up to a maximum of 359 months for Pemetexed and 180 months for Pacsbo. However, it is not clear what the values at the beginning of the text ("o 3 & 9 2 15w 2 u ;W W 0B") represent, so it is not possible to provide a more detailed description.*

This is a medical data table, showing data related to survival probability in cancer patients. The table contains two sets of data, one for a treatment involving Cisplatin and another for Pemetrexed + Cisplatin. The table includes data related to patients at risk, survival time in months, and the survival probability. This table can be useful for doctors to evaluate the effectiveness of different treatment options for cancer patients.*

This is a description for a drug with LOT number PXXNNNNN and EXP date of MMM.YYYY. The drug's NDC code is 16720-522.05 R. It is an injection containing 25mg of Eliquis, 2157mg of pemetrexed dsodium, 15mg of citic zcid, among other ingredients. The drug should be stored between 68°F to 77°F. After dilution, the solution should be kept refrigerated between 36°F to 46°F for up to 24 hours. The recommended dosage is not provided in this text. The drug is manufactured by Intas Pharmaceuticals Limited and distributed by Accerd Healthcare, Inc. This drug is labeled as hazardous.*

This is a description for Pemetrexed Injection, a hazardous drug used for intravenous infusion after dilution, available in single-dose vials containing 850 mg/34 mL (25 mg/mL) of the drug. Each milliliter of the drug contains 25 mg of pemetrexed disodium, 15 mg of citric acid anhydrous, 0.5 mg of L-methionine, 4.4 mg of monosodium glycerol, and water for injection. The storage temperature of the drug is 20°C to 25°C, with excursions permitted between 15°C to 0°C. Diluted solutions of the drug can be refrigerated for up to 24 hours. The recommended dosage information is not available. The drug is manufactured by Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-362 213, INDIA, and distributed by Accord Healthcare, Inc., Durham, NC 27703.*

This is a description of Pemetrexed Injection medication. Each mL of the solution contains 25 mg of pemelrexed. The storage should be kept in its original packaging to protect it from light, at a temperature between 20°C and 26°C. The medication is for intravenous use, and it is recommended to be diluted before infusion. The text provides details regarding the recommended dosage, quantity, and its NDC code.*

This is a description of Pemetrexed Injection Griyaris which is a drug that comes in a bottle that contains 25 mg of pemetrexed. The drug is only accessible via prescription and must be administered through intravenous infusion. The container consists of other substances such as citric acid, L mettiorine, and water with 100 mgjé mi monothioghcerol. The pH of the medication is adusted using hydrochloric acid and sodium hydroxide. The drug must be kept between 20°C to 25°C (B6°F to 77°F) and it's advisable to store it in the original carton to protect it from light. This information is for Accord Heallhcars, Inc, and the drug is Made in India. The description also contains Lot and Exp codes for the drug.*